Department of Pathology, College of Medicine, University of the Philippines Manila, Manila, Philippines
© 2017 The Korean Society of Pathologists/The Korean Society for Cytopathology
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Study | Hospital | Year | Distribution by the Bethesda categories (%) |
Nodule | |||||
---|---|---|---|---|---|---|---|---|---|
I | II | III | IV | V | VI | ||||
Young et al. (2011) [24] | St. Luke’s Medical Center, Quezon City | 2007–2009 | 23.1 | 64.7 | 9.4 |
2.8 | 2,239 | ||
Salillas and Almocera (2016) [25] | Private practice, Cebu City and Bohol | 2010–2014 | 1.3 | 56.2 | 5.4 | 11.1 | 13.2 | 12.8 | 3,799 |
Study | Hospital | Year | Risk of malignancy for the Bethesda categories (%) |
Nodule | |||||
---|---|---|---|---|---|---|---|---|---|
I | II | III | IV | V | VI | ||||
Young et al. (2011) [24] | St. Luke’s Medical Center, Quezon City | 2007–2009 | 17.2 | 9.6 | 36.5 |
76.5 | 251 | ||
Abelardo et al. (2011) [15] | Philippine General Hospital, Manila | 2010 | 44.4 | 18.9 | 40.0 | 44.4 | 60.0 | 100.0 | 99 |
Canete et al. (2014) [19] | Philippine General Hospital, Manila | 2008–2011 | n/a | 32.0 | n/a | 41.4 | 89.7 | 100.0 | 837 |
Carlos et al. (2014) [22] | St. Luke’s Medical Center, Quezon City | 2012–2013 | n/a | n/a | 35.3 | n/a | n/a | n/a | 68 |
Ramos and Mirasol (2014) [16] | St. Luke’s Medical Center, Quezon City | 2012–2013 | 33.3 | 13.5 | 22.2 | 33.3 | 72.2 | 100.0 | 175 |
Salillas et al. (2015) [23] | SWU-MHAM College of Medicine, Cebu City | 2009–2012 | n/a | 2.6 | 50.0 | 50.0 | 78.0 | 100.0 | 80 |
Salillas and Almocera (2016) [25] | Private practice, Cebu City and Bohol | 2010–2014 | n/a | n/a | 39.4 | n/a | n/a | n/a | 33 |
Abelardo and Abesamis (2016) [14] | The Medical City, Pasig City | 2010–2015 | n/a | 26.5 | n/a | n/a | 71.4 |
448 | |
The Bethesda system reference rate [11] | 1–4 | 0–3 | 5–15 | 15–30 | 60–75 | 97–99 |
Sum of indeterminate categories III to V: classified as “indeterminate.”
n/a, not available. Sum of indeterminate categories III to V: classified as “indeterminate”; Overall risk of malignancy for suspicious for malignancy and malignant cases.